New House Bill calls for change in CMS definition of radiopharmaceuticals

For years hospitals offering Nuclear Medicine imaging services have been at a disadvantage because the cost of the radiopharmaceutical is bundled with the technical fee into a single reimbursement by Medicare.

For years hospitals offering Nuclear Medicine imaging services have been at a disadvantage because the cost of the radiopharmaceutical is bundled with the technical fee into a single reimbursement by Medicare. This Bill seeks to alter that situation and have radiopharmaceuticals reclassified from supplies to drugs, thus allowing the clinical provider to bill to recover their cost. Should the Bill gain traction and become law then it will be interesting to see how CMS treats the stand-alone technical component of the imaging study.

Read the rest of the article here.